Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 4/20 | 0.64 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | PLG | P00747 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.46 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7004889 | 1.00 | PAOX (0.64) | PAOXMAOAMAOBALDH1A1ALOX15 | |
| SCHEMBL7007901 | 1.00 | PAOX (0.64) | PAOXMAOAMAOBALDH1A1ALOX15 | |
| SCHEMBL16247098 | 1.00 | PAOX (0.64) | PAOXMAOAMAOBALDH1A1ALOX15 | |
| SCHEMBL944344 | 1.00 | PAOX (0.64) | PAOXMAOAMAOBALDH1A1ALOX15 | |
| SCHEMBL1389554 | 1.00 | PAOX (0.64) | PAOXMAOAMAOBALDH1A1ALOX15 | |
| SCHEMBL3065839 | 1.00 | PAOX (0.64) | PAOXMAOAMAOBALDH1A1ALOX15 | |
| SCHEMBL7010487 | 1.00 | PAOX (0.64) | PAOXMAOAMAOBALDH1A1ALOX15 | |
| Hydrochloric Acid SCHEMBL25353689 | 0.98 | PAOX (0.61) | PAOXMAOAMAOBALDH1A1ALOX15 | |
| Hydrochloric Acid SCHEMBL15155878 | 0.98 | PAOX (0.61) | PAOXMAOAMAOBALDH1A1ALOX15 | |
| Ammonia Solution, Strong SCHEMBL8683457 | 0.98 | PAOX (0.61) | PAOXMAOAMAOBALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4384223-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-06-19 | — | — | EP | disclosed |
| EP-4384224-A1 | CYTOTOXICITY TARGETING CHIMERAS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-06-19 | — | — | EP | disclosed |
| WO-2024010776-A1 | AGENTS WITH TRANSCRIPTION FACTOR TARGETING MOIETIES | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-20240002360-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2024-01-04 | — | — | US | disclosed |
| US-11787778-B2 | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | MONTELINO THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| WO-2023154818-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | MODERNATX, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230192643-A1 | DIHYDROQUINOLINONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023076605-A1 | LIPID AMINES | MODERNATX, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023039603-A2 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | MONTELINO THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | WO | disclosed |
| WO-2023017483-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-02-16 | — | — | WO | disclosed |
| EP-3917916-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | Montelino Therapeutics, Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| US-20210332006-A1 | CARBON DIOXIDE-REVERSIBLY-PROTECTED CHAIN EXTENSION-CROSSLINKING AGENT AND PREPARATION METHOD AND USE THEREOF | CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2021-10-28 | — | — | US | disclosed |
| US-20210292298-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2021-09-23 | — | — | US | disclosed |
| WO-2020160295-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | MONTELINO THERAPEUTICS, LLC (US) | 2020-08-06 | — | — | WO | disclosed |
| US-20200239430-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | MONTELINO THERAPEUTICS, LLC (US) | 2020-07-30 | — | — | US | disclosed |
| US-9447107-B2 | Broadly absorbing metalloporphyrin-based multichromophoric arrays for triplet harvesting | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2016-09-20 | — | — | US | disclosed |
| EP-2697230-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2014-02-19 | — | — | EP | disclosed |
| WO-2012141704-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-18 | — | — | WO | disclosed |
| US-20030225007-A1 | Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases | APOTEX INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1348710-A1 | Sulfonamide derivatives of 3-substituted imidazo[1,2-D]-1,2,4-thiadiazoles and 3-substituted-[1,2,4]thiadiazolo[4,5-A]benzimidazole as inhibitors of fibrin cross-linking and transglutaminases | Apotex Inc. (CA) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787778-B2 | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | AR, ADRM1, PSMA3 | PAOX 849/4885MAOA 2016/4885MAOB 2501/4885 |
| US-20230192643-A1 | DIHYDROQUINOLINONES FOR MEDICAL TREATMENT | CRBN, RBX1, ADRM1 | PAOX 2048/4885MAOA 3897/4885MAOB 3570/4885 |
| US-20200239430-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | PAOX 891/4885MAOA 2092/4885MAOB 2614/4885 |
| US-20240002360-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | PAOX 891/4885MAOA 2092/4885MAOB 2614/4885 |
| US-20210332006-A1 | CARBON DIOXIDE-REVERSIBLY-PROTECTED CHAIN EXTENSION-CROSSLINKING AGENT AND PREPARATION METHOD AND USE THEREOF | MT-CO2, CCNA2, PCNA | PAOX 486/4885MAOA 2529/4885MAOB 2796/4885 |
| US-20210292298-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | PAOX 891/4885MAOA 2092/4885MAOB 2614/4885 |
| US-20030225007-A1 | Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases | PIGS, FGB, SERPINE1 | PAOX 2902/4885MAOA 1597/4885MAOB 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.